Abstract | BACKGROUND: METHODS: In the 'Harmonizing Optimal Strategy for Treatment of coronary artery stenosis - sAfety & effectiveneSS of drug-elUting stents & antiplatelet REgimen' (HOST-ASSURE) trial, approximately 3,750 patients are being prospectively and randomly assigned in a 2 × 2 factorial design according to the type of stent (PtCr-EES vs CoCr-ZES) and antiplatelet regimen (TAT vs DDAT). The first primary endpoint is target lesion failure at 1 year for the stent comparison, and the second primary endpoint is net clinical outcome at 1 month for comparison of antiplatelet therapy regimen. DISCUSSION: The HOST-ASSURE trial is the largest study yet performed to directly compare the efficacy and safety of the PtCr-EES versus CoCr-ZES in an 'all-comers' population. In addition, this study will also compare the clinical outcome of TAT versus DDAT for 1-month post PCI. TRIAL REGISTRATION: ClincalTrials.gov number NCT01267734.
|
Authors | Kyung Woo Park, Byoung-Eun Park, Si-Hyuck Kang, Jin-Joo Park, Seung-Pyo Lee, Kwang Soo Cha, Jay Young Rhew, Hui-Kyoung Jeon, Eun Seok Shin, Ju Hyeon Oh, Myung-Ho Jeong, Sanghyun Kim, Kyung-Kuk Hwang, Jung-Han Yoon, Sung Yun Lee, Tae-Ho Park, Keon Woong Moon, Hyuck-Moon Kwon, In-Ho Chae, Hyo-Soo Kim, HOST investigators |
Journal | Trials
(Trials)
Vol. 13
Pg. 29
(Mar 31 2012)
ISSN: 1745-6215 [Electronic] England |
PMID | 22463698
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Chromium Alloys
- Platelet Aggregation Inhibitors
- Chromium
- Platinum
- Everolimus
- zotarolimus
- Sirolimus
|
Topics |
- Angioplasty, Balloon, Coronary
(adverse effects, instrumentation)
- Chromium
- Chromium Alloys
- Coronary Stenosis
(drug therapy, therapy)
- Drug Therapy, Combination
- Drug-Eluting Stents
- Everolimus
- Humans
- Platelet Aggregation Inhibitors
(adverse effects, therapeutic use)
- Platinum
- Prospective Studies
- Prosthesis Design
- Republic of Korea
- Research Design
- Single-Blind Method
- Sirolimus
(administration & dosage, analogs & derivatives)
- Time Factors
- Treatment Outcome
|